Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
dc.contributor.author | Slamon, D J | |
dc.contributor.author | Neven, P | |
dc.contributor.author | Chia, S | |
dc.contributor.author | Jerusalem, G | |
dc.contributor.author | De Laurentiis, M | |
dc.contributor.author | Im, S | |
dc.contributor.author | Petrakova, K | |
dc.contributor.author | Valeria Bianchi, G | |
dc.contributor.author | Martín, M | |
dc.contributor.author | Nusch, A | |
dc.contributor.author | Sonke, G S | |
dc.contributor.author | De la Cruz-Merino, L | |
dc.contributor.author | Beck, J T | |
dc.contributor.author | Ji, Y | |
dc.contributor.author | Wang, C | |
dc.contributor.author | Deore, U | |
dc.contributor.author | Chakravartty, A | |
dc.contributor.author | Zarate, J P | |
dc.contributor.author | Taran, T | |
dc.contributor.author | Fasching, P A | |
dc.date.accessioned | 2025-01-07T16:00:50Z | |
dc.date.available | 2025-01-07T16:00:50Z | |
dc.date.issued | 2021-08-16 | |
dc.identifier.doi | 10.1016/j.annonc.2021.07.011 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.pmid | 34412950 | |
dc.identifier.unpaywallURL | http://www.annalsofoncology.org/article/S0923753421022092/pdf | |
dc.identifier.uri | https://hdl.handle.net/10668/27558 | |
dc.issue.number | 10 | |
dc.journal.title | Annals of oncology : official journal of the European Society for Medical Oncology | |
dc.journal.titleabbreviation | Ann Oncol | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen del Rocío | |
dc.organization | SAS - Hospital Universitario Virgen Macarena | |
dc.page.number | 1307 | |
dc.pubmedtype | Published Erratum | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 32 |